AU2023224327A1 - Crf2 receptor agonists and their use in therapy - Google Patents

Crf2 receptor agonists and their use in therapy Download PDF

Info

Publication number
AU2023224327A1
AU2023224327A1 AU2023224327A AU2023224327A AU2023224327A1 AU 2023224327 A1 AU2023224327 A1 AU 2023224327A1 AU 2023224327 A AU2023224327 A AU 2023224327A AU 2023224327 A AU2023224327 A AU 2023224327A AU 2023224327 A1 AU2023224327 A1 AU 2023224327A1
Authority
AU
Australia
Prior art keywords
acid
gglu
amino
valine
aib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023224327A
Other languages
English (en)
Inventor
Elisabetta Bianchi
Philip Janiak
Marie-Laure Ozoux
Daniela ROVERSI
Alessia Santoprete
Martina TRIPEPI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corteria Pharmaceuticals
Original Assignee
Corteria Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corteria Pharmaceuticals filed Critical Corteria Pharmaceuticals
Publication of AU2023224327A1 publication Critical patent/AU2023224327A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
AU2023224327A 2022-02-23 2023-02-21 Crf2 receptor agonists and their use in therapy Pending AU2023224327A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22158188.7A EP4234574A1 (en) 2022-02-23 2022-02-23 Crf2 receptor agonists and their use in therapy
EP22158188.7 2022-02-23
PCT/EP2023/054317 WO2023161229A1 (en) 2022-02-23 2023-02-21 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
AU2023224327A1 true AU2023224327A1 (en) 2024-08-29

Family

ID=80819682

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023224327A Pending AU2023224327A1 (en) 2022-02-23 2023-02-21 Crf2 receptor agonists and their use in therapy

Country Status (15)

Country Link
US (1) US20260001928A1 (https=)
EP (2) EP4234574A1 (https=)
JP (1) JP2025508820A (https=)
KR (1) KR20240153565A (https=)
CN (1) CN118843638A (https=)
AU (1) AU2023224327A1 (https=)
CA (1) CA3247142A1 (https=)
ES (1) ES3063881T3 (https=)
HR (1) HRP20260115T1 (https=)
IL (1) IL314055A (https=)
IS (1) IS050770A (https=)
MX (1) MX2024010296A (https=)
PL (1) PL4482578T3 (https=)
WO (1) WO2023161229A1 (https=)
ZA (1) ZA202406196B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025104264A1 (en) * 2023-11-17 2025-05-22 Gubra A/S Hcrhr2 selective polypeptides
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
US20250243255A1 (en) * 2020-08-19 2025-07-31 Sanofi Crf2 receptor agonists and their use in therapy

Also Published As

Publication number Publication date
KR20240153565A (ko) 2024-10-23
IS050770A (is) 2024-10-15
CN118843638A (zh) 2024-10-25
ZA202406196B (en) 2025-03-26
EP4482578C0 (en) 2025-12-24
ES3063881T3 (en) 2026-04-21
EP4482578B1 (en) 2025-12-24
EP4482578A1 (en) 2025-01-01
IL314055A (en) 2024-09-01
HRP20260115T1 (hr) 2026-03-13
EP4234574A1 (en) 2023-08-30
JP2025508820A (ja) 2025-04-10
MX2024010296A (es) 2024-09-18
US20260001928A1 (en) 2026-01-01
WO2023161229A1 (en) 2023-08-31
PL4482578T3 (pl) 2026-03-16
CA3247142A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
CN111491658B (zh) 肠促胰岛素类似物及其用途
KR102440323B1 (ko) 인크레틴 유사체 및 그의 용도
EP4199946B1 (en) Crf2 receptor agonists and their use in therapy
EP4482578B1 (en) Crf2 receptor agonists and their use in therapy
US8450266B2 (en) Analogues of glucose-dependent insulinotropic polypeptide
KR102755938B1 (ko) 변형된 지질화된 릴랙신 b 사슬 펩타이드 및 이들의 치료적 용도
US20110136733A1 (en) Analogues of glucose-dependent insulinotropic polypeptide
US20150252093A1 (en) Glucose-dependent insulinotropic polypeptide analogues
CN114787183A (zh) 肠促胰岛素类似物及其用途
WO2024163535A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
HK40095414A (en) Crf2 receptor agonists and their use in therapy
RU2845766C1 (ru) Агонисты рецептора crf2 и их применение в терапии
HK40112064A (zh) Crf2受体激动剂及其在治疗中的用途
HK40087027B (en) Crf2 receptor agonists and their use in therapy
HK40087027A (en) Crf2 receptor agonists and their use in therapy
JP2026071260A (ja) Ｃｒｆ２受容体アゴニスト及び治療におけるその使用